I certainly agree that, in your words ... "We have a therapy that can effectively treat all solid tumour cancers" would make headlines around the world. I would think that many, if not most holders would be thinking along the same lines as yourself. After all, at each of the recent roadshows, the 'headline act' was Yuman himself, 'Mr CF33'. I believe that he will eventually become the hero of IMU, because CF33 is certainly looking like the 'answer' to cancer. Of course, if they achieve positive data. The CF33 suite is the 'big ticket item' in the current IMU suite ... and they are trying to get the message out there. This doesn't mean, in my view, that it will be the first deal. It might be, and what a blockbuster it would be, but little HER-Vaxx may beat it to the first deal ... especially if they get a great data read out in a Keytruda-HER-vaxx combo.
Hi Wasa @Wasabibarako You certainly could be right, the deal may need to come first. It would be a much more powerful NASDAQ entry then. I also like your positivity around the timing ... ie. Q2. That would suit me and everyone on these threads. I have my fingers and toes crossed that you are right.
As Wasa says ... have a lovely weekend. Who knows what Monday may bring. Wink, wink.
All opinion only of course.
IMU Price at posting:
13.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)